MCID: PTT009
MIFTS: 59

Pituitary Gland Disease

Categories: Endocrine diseases

Aliases & Classifications for Pituitary Gland Disease

MalaCards integrated aliases for Pituitary Gland Disease:

Name: Pituitary Gland Disease 12 15 17
Pituitary Dysfunction 56 74
Pituitary Diseases 56 74
Pituitary Disorders 44
Pituitary Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:53
ICD9CM 36 253.1
ICD10 34 E23.6

Summaries for Pituitary Gland Disease

MedlinePlus : 44 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. With pituitary disorders, you often have too much or too little of one of your hormones. Injuries can cause pituitary disorders, but the most common cause is a pituitary tumor.

MalaCards based summary : Pituitary Gland Disease, also known as pituitary dysfunction, is related to galactorrhea and hypoadrenalism, and has symptoms including seizures, tremor and back pain. An important gene associated with Pituitary Gland Disease is PRL (Prolactin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Immune response IFN alpha/beta signaling pathway. The drugs Dexmedetomidine and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 An endocrine system disease that is located in the pituitary gland.

Wikipedia : 77 A pituitary disease is a disorder primarily affecting the pituitary... more...

Related Diseases for Pituitary Gland Disease

Diseases related to Pituitary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 galactorrhea 30.2 IGF1 PRL
2 hypoadrenalism 30.1 CRH GH1 POMC
3 growth hormone deficiency 30.0 GH1 GHRH HESX1 IGF1
4 fibromyalgia 29.9 CRH IGF1 PRL
5 acth-secreting pituitary adenoma 29.8 CRH POMC PRL
6 mccune-albright syndrome 29.7 GH1 IGF1 PRL SST
7 inappropriate adh syndrome 29.7 AVP POMC
8 polycystic ovary syndrome 29.7 GNRH1 IGF1 INS PRL
9 ovarian disease 29.7 GNRH1 IGF1 INS PRL
10 secondary adrenal insufficiency 29.6 AVP IGF1 INS
11 multiple endocrine neoplasia, type i 29.6 GHRH INS MEN1 PRL SST
12 adenohypophysitis 29.5 GH1 POMC PRL TRH
13 anorexia nervosa 29.5 CRH GH1 GHRH IGF1 POMC PRL
14 conn's syndrome 29.3 CRH GH1 MEN1 POMC PRL SST
15 hypopituitarism 29.3 CRH GH1 GHRH GNRH1 HESX1 IGF1
16 diabetes insipidus 29.2 AVP CRH INS POMC PRL
17 amenorrhea 29.1 CRH GNRH1 POMC PRL TRH
18 gigantism 29.1 AIP GH1 GHRH PRL
19 empty sella syndrome 29.0 GH1 GNRH1 IGF1 POMC PRL TRH
20 hyperprolactinemia 28.8 GH1 GNRH1 IGF1 POMC PRL SST
21 craniopharyngioma 28.6 GH1 GNRH1 IGF1 INS POU1F1 PRL
22 hypothyroidism, congenital, nongoitrous, 4 28.4 CRH GH1 IGF1 POMC POU1F1 PRL
23 hypothyroidism 28.1 GH1 HESX1 IGF1 LHX3 POMC POU1F1
24 pituitary tumors 27.9 AIP GH1 IGF1 MEN1 POMC POU1F1
25 acromegaly 27.5 AIP GH1 GHRH IGF1 INS MEN1
26 microphthalmia, syndromic 5 11.9
27 pallister-hall syndrome 11.8
28 optic nerve hypoplasia, bilateral 11.3
29 laurence-moon syndrome 11.0
30 hypothyroidism, central, and testicular enlargement 11.0
31 culler-jones syndrome 11.0
32 fibrous dysplasia/mccune-albright syndrome 10.5 GH1 PRL
33 brain injury 10.5
34 bronchus adenoma 10.4 POMC SST
35 traumatic brain injury 10.4
36 bronchial adenomas/carcinoids childhood 10.4 POMC SST
37 lymphocytic hypophysitis 10.4 GH1 POMC
38 non-functioning pituitary adenoma 10.4 GH1 SST
39 scleredema adultorum 10.4 INS POMC
40 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.4 IGF1 INS
41 allergic encephalomyelitis 10.4 CRH POMC
42 acidophil adenoma 10.4 IGF1 POMC SST
43 prolactin producing pituitary tumor 10.4 PRL SST
44 pancreatic somatostatinoma 10.4 MEN1 SST
45 duodenal somatostatinoma 10.3 INS SST
46 neonatal thyrotoxicosis 10.3 LHX3 PROP1
47 postgastrectomy syndrome 10.3 INS SST
48 hypogonadotropism 10.3 GNRH1 PRL
49 gangliocytoma 10.3 CRH POMC
50 acanthosis nigricans 10.3 IGF1 INS PRL

Graphical network of the top 20 diseases related to Pituitary Gland Disease:



Diseases related to Pituitary Gland Disease

Symptoms & Phenotypes for Pituitary Gland Disease

UMLS symptoms related to Pituitary Gland Disease:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Pituitary Gland Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.33 AIP CRH GHRH GNRH1 HESX1 IGF1
2 homeostasis/metabolism MP:0005376 10.31 AIP AVP CRH GHRH GNRH1 IGF1
3 growth/size/body region MP:0005378 10.28 AIP CRH GHRH GNRH1 HESX1 IGF1
4 immune system MP:0005387 10.07 CRH GHRH GNRH1 IGF1 INS MEN1
5 mortality/aging MP:0010768 10.03 AIP AVP HESX1 IGF1 INS LHX3
6 liver/biliary system MP:0005370 9.92 AIP CRH GHRH GNRH1 INS MEN1
7 nervous system MP:0003631 9.86 AVP CRH GHRH GNRH1 HESX1 IGF1
8 neoplasm MP:0002006 9.63 AIP GNRH1 IGF1 MEN1 POMC PRL
9 reproductive system MP:0005389 9.28 GHRH GNRH1 IGF1 INS LHX3 MEN1

Drugs & Therapeutics for Pituitary Gland Disease

Drugs for Pituitary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 629)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 113775-47-6 68602 5311068
2
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
5
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 120511-73-1 2187
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 3 83919-23-7
8
Metyrapone Approved, Investigational Phase 4,Phase 3 54-36-4 4174
9
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
10
Pasireotide Approved Phase 4,Phase 2,Phase 3,Phase 1 396091-73-9 9941444
11
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
12
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
13
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
14
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
15
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
16
Mecasermin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68562-41-4
17
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
18
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
19
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
20
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0, 481-30-1 6013 10204
21
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 315-37-7 9416
22
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-18-4 6010
23
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 5949-44-0
24
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
25
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 7440-66-6 32051
26
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
27
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 81409-90-7 54746
28
Tolvaptan Approved Phase 4,Phase 3,Phase 1,Phase 2 150683-30-0 216237
29
Ganirelix Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123246-29-7, 124904-93-4 25081094
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
32
Leuprolide Approved, Investigational Phase 4,Not Applicable 53714-56-0 657181 3911
33
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 28014-46-2
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
35
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
36
Acetaminophen Approved Phase 4 103-90-2 1983
37
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
38
Morphine Approved, Investigational Phase 4 57-27-2 5288826
39
Ibuprofen Approved Phase 4 15687-27-1 3672
40
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 302-25-0
41
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
42
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1 2921-57-5
44
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
45
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 51-45-6 774
46
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 1 90566-53-3 62924
47
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
48
Sodium oxybate Approved Phase 4 502-85-2 5360545
49
Menotropins Approved Phase 4,Phase 2,Not Applicable 9002-68-0, 61489-71-2 5360545
50
Cetrorelix Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 120287-85-6 25074887 16129715

Interventional clinical trials:

(show top 50) (show all 1116)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
4 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
5 Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism Unknown status NCT02282150 Phase 4 Hydrocortisone;Plenadren
6 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
7 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
8 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Unknown status NCT02976675 Phase 4
9 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Unknown status NCT02908958 Phase 4
10 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
11 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
12 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
13 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
14 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
15 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
16 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
17 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
18 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
19 Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis Completed NCT01154153 Phase 4 Placebo nasal spray;Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ);Placebo nasal spray;Claritin® Syrup
20 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
21 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
22 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
23 Testosterone Gel Applied to Women With Pituitary Gland Problems Completed NCT00144391 Phase 4 Transdermal Testosterone gel
24 Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population Completed NCT01137032 Phase 4 Pandel Cream 0.1%
25 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
26 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
27 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
28 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
29 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
30 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
31 Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) Completed NCT00449072 Phase 4 TAA-AQ, Nasacort® AQ;Claritin®
32 Effect of DPP4 Inhibition on Growth Hormone Secretion Completed NCT01701973 Phase 4 Sitagliptin;Pegvisomant;Placebo;L-NMMA;Exendin 9-39
33 Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study Completed NCT02204826 Phase 4 Korean Red Ginseng (KRG)
34 Viapaed Study In Children And Adolescents With Asthma Completed NCT00315744 Phase 4 Salmeterol/fluticasone;Fluticasone propionate;Salbutamol
35 Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF) Completed NCT01225835 Phase 4 Menotrophin;Follitrophin alpha;Cetrorelix;Choriongonadotropin;Progesterone
36 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
37 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
38 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
39 Easypod United States User Trial Completed NCT00689260 Phase 4
40 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
41 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
42 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
43 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
44 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
45 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
46 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
47 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
48 IGF1 Generation Test Completed NCT00145457 Phase 4
49 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
50 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR

Search NIH Clinical Center for Pituitary Gland Disease

Genetic Tests for Pituitary Gland Disease

Anatomical Context for Pituitary Gland Disease

MalaCards organs/tissues related to Pituitary Gland Disease:

42
Pituitary, Brain, Testes, Bone, Ovary, Thyroid, Heart

The Foundational Model of Anatomy Ontology organs/tissues related to Pituitary Gland Disease:

20
The Pituitary Gl

Publications for Pituitary Gland Disease

Articles related to Pituitary Gland Disease:

(show top 50) (show all 178)
# Title Authors Year
1
The history of pituitary dysfunction after traumatic brain injury. ( 30825117 )
2019
2
The role of autoimmunity in pituitary dysfunction due to traumatic brain injury. ( 30847776 )
2019
3
Impact of pituitary dysfunction on cognitive and global outcome after traumatic brain injury and aneurysmal subarachnoid haemorrhage. ( 30761404 )
2019
4
A clinical and pathophysiological approach to traumatic brain injury-induced pituitary dysfunction. ( 30734143 )
2019
5
Pituitary dysfunction due to sports-related traumatic brain injury. ( 30637622 )
2019
6
The frequency and the diagnosis of pituitary dysfunction after traumatic brain injury. ( 30684166 )
2019
7
A 61 year old man with pancreatitis, pituitary dysfunction, and painful exophthalmos. ( 30792233 )
2019
8
PITUITARY STALK THICKENING IN A LARGE COHORT - TOWARDS MORE ACCURATE PREDICATORS OF PITUITARY DYSFUNCTION AND ETIOLOGY. ( 30865546 )
2019
9
Patterns of pituitary dysfunction three months or more after traumatic brain injury. ( 30319953 )
2018
10
Posterior pituitary dysfunction following traumatic brain injury: review. ( 30334138 )
2018
11
Sports-Related Repetitive Traumatic Brain Injury: A Novel Cause of Pituitary Dysfunction. ( 30156462 )
2018
12
Pituitary dysfunction and association with fatigue in stroke and other acute brain injury. ( 29748174 )
2018
13
Hypothalamic and pituitary dysfunction is common in tubercular meningitis: A prospective study from a tertiary care center in Northern India. ( 30321796 )
2018
14
Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. ( 30324794 )
2018
15
Pituitary Dysfunction in Pediatric Patients with Optic Nerve Hypoplasia: A Retrospective Cohort Study (1975-2014). ( 29176324 )
2018
16
Reflex and reflective testing strategies for early detection of pituitary dysfunction. ( 29486187 )
2018
17
Pituitary Dysfunction from an Unruptured Ophthalmic Internal Carotid Artery Aneurysm with Improved 2-year Follow-up Results: A Case Report. ( 29675480 )
2018
18
Pituitary dysfunction in survivors of Russell's viper snake bite envenomation: A prospective study. ( 30233002 )
2018
19
Melatonin prevents early pituitary dysfunction induced by sucrose-rich diets. ( 30586198 )
2018
20
Sellar plasmacytoma presenting with symptoms of anterior pituitary dysfunction. ( 29204279 )
2017
21
RETRACTION Novel perspectives on hypothalamic-pituitary dysfunction as a risk factor for non-alcoholic fatty liver disease. ( 27405476 )
2017
22
Pituitary dysfunction in granulomatosis with polyangiitis. ( 28540625 )
2017
23
Assessment of the role of intracranial hypertension and stress on hippocampal cell apoptosis and hypothalamic-pituitary dysfunction after TBI. ( 28630478 )
2017
24
Plasminogen Activator Inhibitor Type 1: A Possible Novel Biomarker of Late Pituitary Dysfunction after Mild Traumatic Brain Injury. ( 28931364 )
2017
25
The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidance. ( 28860331 )
2017
26
Pituitary dysfunction after traumatic brain injury: are there definitive data in children? ( 27872046 )
2017
27
Pituitary dysfunction in traumatic brain injury: Is evaluation in the acute phase worthwhile? ( 28217503 )
2017
28
Giant cavernous carotid aneurysm causing pituitary dysfunction: Pituitary function recovery with high-flow bypass. ( 28868192 )
2017
29
IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction. ( 27083162 )
2016
30
Systemic sarcoidosis with hypercalcaemia, hypothalamic-pituitary dysfunction and thyroid involvement. ( 27495178 )
2016
31
Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. ( 26501843 )
2016
32
Incidence of pituitary dysfunction following traumatic brain injury: A prospective study from a regional neurosurgical centre. ( 26610235 )
2016
33
Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis. ( 26645970 )
2016
34
Pituitary dysfunction and its association with quality of life in traumatic brain injury. ( 26708846 )
2016
35
Reduced Quality of Life in Patients with Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Prospective Longitudinal Study. ( 26724609 )
2016
36
Clinical prevalence and outcome impact of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review with meta-analysis. ( 27287036 )
2016
37
Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department. ( 27451306 )
2016
38
Pituitary dysfunction after aneurysmal subarachnoid hemorrhage in Japanese patients. ( 27492047 )
2016
39
Can early clinical parameters predict post-traumatic pituitary dysfunction in severe traumatic brain injury? ( 27778105 )
2016
40
Prevalence of hypothalamo pituitary dysfunction in patients of traumatic brain injury. ( 27867878 )
2016
41
Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury. ( 26252757 )
2015
42
Hypothalamic pituitary dysfunction amongst nasopharyngeal cancer survivors. ( 25134488 )
2015
43
Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study. ( 25378238 )
2015
44
High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing. ( 25514615 )
2015
45
Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage. ( 25681597 )
2015
46
Early identification of pituitary dysfunction in congenital nasal pyriform aperture stenosis: recommendations based on experience in a single centre. ( 25791686 )
2015
47
Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. ( 25950715 )
2015
48
Neutrophil function in healthy aged horses and horses with pituitary dysfunction. ( 25962580 )
2015
49
PITUITARY DYSFUNCTION IN DEVELOPMENTAL DELAY: MEDICAL AND ETHICAL CONCERNS. ( 26121462 )
2015
50
Pituitary dysfunction following traumatic brain injury: clinical perspectives. ( 26251600 )
2015

Variations for Pituitary Gland Disease

Expression for Pituitary Gland Disease

Search GEO for disease gene expression data for Pituitary Gland Disease.

Pathways for Pituitary Gland Disease

GO Terms for Pituitary Gland Disease

Cellular components related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 AVP CRH GH1 GHRH GNRH1 IGF1
2 secretory granule GO:0030141 9.43 AVP POMC TRH
3 extracellular region GO:0005576 9.36 AVP CRH GH1 GHRH GNRH1 IGF1
4 endosome lumen GO:0031904 9.33 GH1 INS PRL

Biological processes related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.88 IGF1 INS MEN1 PRL
2 positive regulation of cell proliferation GO:0008284 9.87 AVP CRH GHRH IGF1 INS POU1F1
3 animal organ morphogenesis GO:0009887 9.8 LHX3 LHX4 PROP1
4 female pregnancy GO:0007565 9.79 CRH GNRH1 PRL
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 GH1 IGF1 INS
6 positive regulation of multicellular organism growth GO:0040018 9.69 GH1 GHRH POU1F1
7 response to organic cyclic compound GO:0014070 9.67 AVP GNRH1 TRH
8 positive regulation of glycolytic process GO:0045821 9.64 IGF1 INS
9 response to corticosterone GO:0051412 9.63 CRH TRH
10 pituitary gland development GO:0021983 9.63 HESX1 LHX3 POU1F1
11 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.62 AVP IGF1
12 positive regulation of glycogen biosynthetic process GO:0045725 9.62 IGF1 INS
13 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 PRL
14 negative regulation of feeding behavior GO:2000252 9.57 INS TRH
15 hormone-mediated apoptotic signaling pathway GO:0008628 9.55 CRH SST
16 somatotropin secreting cell differentiation GO:0060126 9.54 POU1F1 PROP1
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.54 GH1 GHRH IGF1
18 cell-cell signaling GO:0007267 9.5 AVP GHRH GNRH1 INS POMC SST
19 positive regulation of lactation GO:1903489 9.48 GHRH PRL
20 response to ethanol GO:0045471 9.46 AVP CRH GNRH1 TRH
21 medial motor column neuron differentiation GO:0021526 9.43 LHX3 LHX4
22 adenohypophysis development GO:0021984 9.43 GHRH POU1F1 PROP1
23 regulation of signaling receptor activity GO:0010469 9.32 AVP GH1 GHRH GNRH1 IGF1 INS
24 parturition GO:0007567 9.3 CRH
25 ovulation cycle GO:0042698 9.29 GNRH1
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 IGF1 LHX3 LHX4 MEN1 POMC POU1F1
27 G protein-coupled receptor signaling pathway GO:0007186 10.01 AVP CRH GHRH GNRH1 INS POMC
28 negative regulation of apoptotic process GO:0043066 10 AVP GNRH1 IGF1 LHX3 LHX4 PROP1

Molecular functions related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.72 HESX1 LHX3 LHX4 POU1F1 PROP1
2 hormone activity GO:0005179 9.36 AVP CRH GH1 GHRH GNRH1 IGF1
3 neuropeptide hormone activity GO:0005184 9.33 AVP CRH GHRH
4 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS
5 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....